جدول الترويج UroGen Pharma Ltd.
الجدول الزمني المتقدم
رسم بياني بسيط
عن الشركة UroGen Pharma Ltd.
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. مزيد من التفاصيل| IPO date | 2017-05-04 |
|---|---|
| ISIN | IL0011407140 |
| Industry | Biotechnology |
| Sector | Health Care |
| Валюта | usd |
| Валюта отчета | usd |
| Сайт | https://www.urogen.com |
| Цена ао | 11.52 |
| تغير السعر يوميا: | 0% (11.45) |
|---|---|
| تغير السعر في الأسبوع: | -5.61% (12.13) |
| تغير السعر شهريا: | +22.33% (9.36) |
| تغير السعر خلال 3 أشهر: | +6.41% (10.76) |
| تغير السعر على مدى ستة أشهر: | -9.84% (12.7) |
| تغير السعر سنويا: | -23.67% (15) |
| تغير السعر على مدى 3 سنوات: | +31.76% (8.69) |
| تغير السعر على مدى 5 سنوات: | -59.12% (28.01) |
| تغير الأسعار منذ بداية العام: | +3.71% (11.04) |
|
|
الاستهانة
|
كفاءة
|
|||||||||||||||||||||||||||||||||||||
توزيعات الأرباح
|
واجب
|
دافع النمو
|
|||||||||||||||||||||||||||||||||||||
| المؤسسات | مقدار | يشارك, % |
|---|---|---|
| Great Point Partners LLC | 2620545 | 8.49 |
| Menora Mivtachim Holdings Ltd. | 2303031 | 7.46 |
| RA Capital Management, L.P. | 1483697 | 4.81 |
| Blackrock Inc. | 1197647 | 3.88 |
| Credit Suisse Ag/ | 1060000 | 3.43 |
| Harel Insurance Investments & Financial Services Ltd. | 870194 | 2.82 |
| RTW Investments LP | 857464 | 2.78 |
| Migdal Insurance & Financial Holdings Ltd. | 648302 | 2.1 |
| SILVERARC CAPITAL MANAGEMENT, LLC | 508883 | 1.65 |
| Wildcat Capital Management, LLC | 495606 | 1.61 |
| مشرف | مسمى وظيفي | قسط | سنة الميلاد |
|---|---|---|---|
| Ms. Elizabeth A. Barrett | President, CEO & Director | 1.12M | 1962 (63 سنة) |
| Mr. Dong Kim | Chief Financial Officer | 546.68k | 1977 (48 سنين) |
| Mr. Jason Drew Smith | General Counsel, Chief Compliance Officer & Corporate Secretary | 717.58k | 1972 (53 سنة) |
| Vincent I. Perrone | Senior Director of Investor Relations | N/A | |
| Mr. Bryon Wornson | Executive Vice President of Talent, Advocacy & Communications | N/A | |
| Dr. Mark P. Schoenberg M.D. | Chief Medical Officer | 579.5k | 1958 (67 سنين) |
| Mr. James Ottinger R.ph. | Executive Vice President of Regulatory Affairs & Quality | N/A | |
| Dr. Marina Konorty Ph.D. | Executive Vice President of Research & Development and Technical Operations | ||
| Dr. Polly A. Murphy D.V.M., M.B.A., Ph.D. | Chief Business Officer | 1965 (60 سنين) | |
| Mr. Michael J. Louie M.D., M.P.H., M.Sc. | Senior Vice President of Medical Affairs & Clinical Development |
عنوان: United States, Princeton. NJ, 400 Alexander Park - مفتوحة في خرائط جوجل, فتح خرائط ياندكس
موقع إلكتروني: https://www.urogen.com
موقع إلكتروني: https://www.urogen.com
